Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Merck KGaA/Pfizer's 90 day exclusivity period in effect now

<< Previous

Bullboard Posts

Next >>

Comment by fox7mfon Nov 23, 2022 12:56pm

239 Views

Post# 35122473

RE:RE:RE:RE:RE:RE:RE:RE:Merck KGaA/Pfizer's 90 day exclusivity period in effect now

PFE has had real time access to Bracelet data during this process. If results weren't going Oncy's way Pfizer would have bolted a long while ago. The 90 day exclusivity may take some pressure off of PFE, but not much...they know Goblet results...they know Aware results are expected to be similarly stellar...they know Roche is probably negotiating with Onc. Knowing that a Roche offer could come at anytime is making the 90 day exclusivity period much less of a luxury. Strike now or lose out.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario